Literature DB >> 11239788

Tuberculosis vaccine development: recent progress.

I M Orme1, D N McMurray, J T Belisle.   

Abstract

Recent years have seen a renewed effort to develop new vaccines against tuberculosis. As a result, several promising avenues of research have developed, including the production of recombinant vaccines, auxotrophic vaccines, DNA vaccines and subunit vaccines. In this article we briefly review this work, as well as consider the pros and cons of the animal models needed to test these new vaccines. Screening to date has been carried out in mouse and guinea pig models, which have been used to obtain basic information such as the effect of the vaccine on bacterial load, and whether the vaccine can prevent or reduce lung pathology. The results to date lead us to be optimistic that new candidate vaccines could soon be considered for evaluation in clinical trials.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11239788     DOI: 10.1016/s0966-842x(00)01949-1

Source DB:  PubMed          Journal:  Trends Microbiol        ISSN: 0966-842X            Impact factor:   17.079


  36 in total

1.  Establishment of an aerosol challenge model of tuberculosis in rhesus macaques and an evaluation of endpoints for vaccine testing.

Authors:  S A Sharpe; H McShane; M J Dennis; R J Basaraba; F Gleeson; G Hall; A McIntyre; K Gooch; S Clark; N E R Beveridge; E Nuth; A White; A Marriott; S Dowall; A V S Hill; A Williams; P D Marsh
Journal:  Clin Vaccine Immunol       Date:  2010-06-09

2.  Stable T-cell population expressing an effector cell surface phenotype in the lungs of mice chronically infected with Mycobacterium tuberculosis.

Authors:  Ana Paula Junqueira-Kipnis; Joanne Turner; Mercedes Gonzalez-Juarrero; Oliver C Turner; Ian M Orme
Journal:  Infect Immun       Date:  2004-01       Impact factor: 3.441

3.  Magnetic resonance imaging of pulmonary lesions in guinea pigs infected with Mycobacterium tuberculosis.

Authors:  Susan L Kraft; Deanna Dailey; Matthew Kovach; Karen L Stasiak; Jamie Bennett; Christine T McFarland; David N McMurray; Angelo A Izzo; Ian M Orme; Randall J Basaraba
Journal:  Infect Immun       Date:  2004-10       Impact factor: 3.441

4.  Protective effect of a tuberculosis subunit vaccine based on a fusion of antigen 85B and ESAT-6 in the aerosol guinea pig model.

Authors:  Anja W Olsen; Ann Williams; Limei M Okkels; Graham Hatch; Peter Andersen
Journal:  Infect Immun       Date:  2004-10       Impact factor: 3.441

5.  Tracking antigen-specific CD8 T lymphocytes in the lungs of mice vaccinated with the Mtb72F polyprotein.

Authors:  Scott M Irwin; Angelo A Izzo; Steven W Dow; Y A W Skeiky; Steven G Reed; Mark R Alderson; Ian M Orme
Journal:  Infect Immun       Date:  2005-09       Impact factor: 3.441

6.  CHO expressed recombinant human lactoferrin as an adjuvant for BCG.

Authors:  Shen-An Hwang; Marian L Kruzel; Jeffrey K Actor
Journal:  Int J Immunopathol Pharmacol       Date:  2015-08-27       Impact factor: 3.219

7.  Memory T lymphocytes generated by Mycobacterium bovis BCG vaccination reside within a CD4 CD44lo CD62 ligand(hi) population.

Authors:  Andre Kipnis; Scott Irwin; Angelo A Izzo; Randall J Basaraba; Ian M Orme
Journal:  Infect Immun       Date:  2005-11       Impact factor: 3.441

8.  Reduced local growth and spread but preserved pathogenicity of a DeltapurC Mycobacterium tuberculosis auxotrophic mutant in gamma interferon receptor-deficient mice after aerosol infection.

Authors:  Najmeeyah Brown; Muazzam Jacobs; Shreemanta K Parida; Tania Botha; Aldina Santos; Lizette Fick; Brigitte Gicquel; Mary Jackson; Valerie Quesniaux; Bernhard Ryffel
Journal:  Infect Immun       Date:  2005-01       Impact factor: 3.441

9.  A novel recombinant human lactoferrin augments the BCG vaccine and protects alveolar integrity upon infection with Mycobacterium tuberculosis in mice.

Authors:  Shen-An Hwang; Katarzyna Wilk; Marian L Kruzel; Jeffrey K Actor
Journal:  Vaccine       Date:  2009-04-05       Impact factor: 3.641

10.  Capture of heat-killed Mycobacterium bovis bacillus Calmette-Guérin by intelectin-1 deposited on cell surfaces.

Authors:  Shoutaro Tsuji; Makiko Yamashita; Donald R Hoffman; Akihito Nishiyama; Tsutomu Shinohara; Takashi Ohtsu; Yoshimi Shibata
Journal:  Glycobiology       Date:  2009-01-29       Impact factor: 4.313

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.